title: Is tenofovir/emtricitabine teratogenic?
abstract: The Truvada(®) (tenofovir/emtricitabine) and nevirapine combination is increasingly being prescribed for prevention of mother-to-child HIV transmission. There is presently no documented evidence of teratogenicity of either tenofovir/emtricitabine or nevirapine. We report two cases of spina bifida in infants of mothers on this drug combination.
authors.affiliation: Department of Pharmacology, Faculty of Medicine, Bayero University Kano, Kano State, Nigeria and Alnoury Hospital, Kano, Kano State, Nigeria.
authors.forename: Murtala
authors.initials: M
authors.lastname: Jibril
authors.affiliation: Academic Division of Child Health, University of Nottingham, Derbyshire Children's Hospital, Derby, UK.
authors.forename: Oluwaseun
authors.initials: O
authors.lastname: Egunsola
keywords: emtricitabine; nevirapine; pregnancy; spina bifida; tenofovir; teratogenicity
references.citation: Reprod Toxicol. 2003 Jan-Feb;17(1):95-108
references.pmid: 12507664
references.citation: Q J Med. 1993 Nov;86(11):703-8
references.pmid: 8265769
references.citation: J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):183-7
references.pmid: 21084995
references.citation: Lancet. 1991 Jul 20;338(8760):131-7
references.pmid: 1677062
references.citation: Congenit Anom (Kyoto). 2006 Jun;46(2):55-67
references.pmid: 16732763
references.citation: PLoS Med. 2012;9(5):e1001217
references.pmid: 22615543
references.citation: AIDS. 2012 Jun 1;26(9):1167-9
references.pmid: 22592070